BioSig Technologies (NASDAQ:BSGM) Trading Down 8.4%

BioSig Technologies, Inc. (NASDAQ:BSGM) shares traded down 8.4% on Friday . The company traded as low as $1.35 and last traded at $1.41. 199,537 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 983,634 shares. The stock had previously closed at $1.54.

BioSig Technologies Stock Down 8.4 %

The stock has a market capitalization of $15.79 million, a price-to-earnings ratio of -0.29 and a beta of 1.21. The business has a 50-day simple moving average of $0.78 and a two-hundred day simple moving average of $2.63.

Institutional Investors Weigh In On BioSig Technologies

A number of institutional investors have recently added to or reduced their stakes in BSGM. Armistice Capital LLC acquired a new stake in shares of BioSig Technologies during the 4th quarter valued at $2,660,000. Vanguard Group Inc. lifted its position in shares of BioSig Technologies by 44.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,383,866 shares of the company’s stock valued at $1,166,000 after acquiring an additional 729,856 shares during the last quarter. Advisor Resource Council lifted its position in shares of BioSig Technologies by 19.6% during the 3rd quarter. Advisor Resource Council now owns 1,077,906 shares of the company’s stock valued at $527,000 after acquiring an additional 176,700 shares during the last quarter. BlackRock Inc. lifted its position in shares of BioSig Technologies by 32.1% during the 2nd quarter. BlackRock Inc. now owns 594,162 shares of the company’s stock valued at $743,000 after acquiring an additional 144,300 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of BioSig Technologies by 67.0% during the 2nd quarter. Geode Capital Management LLC now owns 565,738 shares of the company’s stock valued at $707,000 after acquiring an additional 227,054 shares during the last quarter. 7.16% of the stock is currently owned by institutional investors and hedge funds.

BioSig Technologies Company Profile

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.